Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Recurrence × Dosage Forms × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 3 Leukemia 3 Stomach Neoplasms 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Vomiting 1 Substance-Related Disorders 1 Solid Tumors 1 Recurrence 1 Pituitary Neoplasms 1 Pancreatic Neoplasms 1 Opioid-Related Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma, Follicular 1 Lymphoma 1 Low Anterior Resection Syndrome 1 Colonic Neoplasms 1 Acromegaly 1

Interventions

Cyclophosphamide 66 Dexamethasone 52 Lenalidomide 37 Peripheral Blood Stem Cell Transplantation 36 Rituximab 35 fludarabine phosphate 34 Bortezomib 30 Filgrastim 27 Etoposide 26 Cytarabine 25 Carboplatin 25 Busulfan 23 Radiotherapy 22 Melphalan 22 Gemcitabine 22 Cyclosporine 21 pomalidomide 20 fludarabine 20 Whole-Body Irradiation 20 Mycophenolic Acid 20 Paclitaxel 19 Methotrexate 18 Cisplatin 17 pembrolizumab 16 Calcium Dobesilate 16 Bevacizumab 16 venetoclax 15 Tacrolimus 14 Antilymphocyte Serum 14 Nivolumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡